A COMPARATIVE STUDY BETWEEN IMATINIB AND NILOTINIB ON ENDOCRINE HORMONAL LEVELS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
Najm T.M.; Shaaban A.A.; Suddek G.M.
Faculty of pharmacy, Mansoura University, Egypt
Chronic myeloid leukemia (CML) is a type of cancer that starts in certain blood-forming cells of the bone marrow. In CML, a genetic change takes place in an early (immature) version of myeloid cells. This change forms an abnormal gene called BCR-ABL, which turns the cell into a CML cell. CML is a fairly slow-growing leukemia, but it can also change into a fast-growing acute leukemia that is hard to treat. Imatinib mesylate and nilotinib; the new Tyrosine Kinase inhibitors (TKIs), were indicated as a frontline for treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) at chronic phase. The aim of this study is to compare between the therapeutic effect of these two drugs in CML patients on endocrine hormonal levels such as T3, T4, TSH, FSH, LH, Prolactin, Progesterone and Testosterone in addition to blood sugar. The results of the current study revealed that Imatinib is generally safer than Nilotinib for endocrine disorders except for hyperglycemia and both drugs were vastly suppressed testosterone and prolactin, so both of them may have beneficial effects in many types of cancer including breast cancer, ovarian cancer, adrenal hyperplasia, pituitary tumors, acromegaly and testicular tumor.